Loading companies…
E
EnginZyme
Sweden · Biotech · Climate tech
EnginZyme develops cell-free biomanufacturing technology that uses immobilized enzymes to make chemicals and ingredients through scalable industrial processes.
Biomanufacturing without living cells
EnginZyme immobilizes enzymes on a proprietary solid support to create stable biocatalysts for multi-step reactions. Instead of relying on cells or conventional batch bioreactors, its cell-free platform can run continuously in fixed-bed reactors used in chemical manufacturing. That gives industrial partners a way to develop processes for producing chemicals and ingredients with biological catalysts while using familiar production equipment.
From process design to commercial scale
The company combines enzyme engineering, biocatalysis, automation and process engineering to develop tailored manufacturing routes. Its products and services cover applications in personal care, food, pharmaceuticals and chemicals, with work extending from feasibility studies through scale-up. EnginZyme’s model is to partner with manufacturers to engineer processes that can be deployed commercially, rather than only supplying a standalone research reagent. Its September financing supports its commercial biomanufacturing strategy.
- Core technology
- Immobilized enzymes for cell-free biomanufacturing
- Process design
- Multi-step reactions in continuous fixed-bed reactors
- Applications
- Chemicals, food, personal care and pharmaceuticals
- Headquarters
- Solna, Sweden
Funding history
1 round · 1 with disclosed amounts| Announced | Round | Amount | Investors |
|---|---|---|---|
| Equity round | SEK 75M | Almi Invest Greentech — ParticipantLotus One Investment — ParticipantNavigare Ventures — ParticipantSofinnova Partners — ParticipantStiftelsen Industrifonden — ParticipantValquest Partners Europe — Participant |
Investors
Almi Invest GreentechJoined Equity roundLotus One InvestmentJoined Equity roundNavigare VenturesJoined Equity roundSofinnova PartnersJoined Equity roundStiftelsen IndustrifondenJoined Equity roundValquest Partners EuropeJoined Equity roundCoverage
Sep 23, 2026EnginZyme · Equity roundSimilar companies
AnaCardioAnaCardio is a clinical-stage biopharmaceutical company developing medicines intended to improve heart muscle function in people with heart failure.€62.5M · Series B
AventixAventix builds sensor-based analytical instruments for laboratories. Its first product, Scarlett 01, measures liquid volumes across microplate wells without touching the sample, helping R&D teams check dispensing quality and catch volume variation before it affects assay results.€1.2M · Pre-seed
NOX EnergyNOX connects home energy devices to electricity markets, optimizing heat pumps and solar systems for household savings and grid flexibility.€3M · Seed